Research Paper Volume 13, Issue 20 pp 23810—23830

CCR5 is a prognostic biomarker and an immune regulator for triple negative breast cancer


Figure 1. (A) CCR5 is overexpressed in basal-like or TNBC subtypes of breast cancer compared to not basal-like or non-TNBC subtypes. (B) The expression of CCR5 is negatively correlated CCR5 promoter methylation levels. (C) Patients with CCR5 high expression have better survivals compared to CCR5 low expression group. (D) CCR5 expression is positively correlated with tumor infiltration immune cells such as B cell, CD8+ T cell, CD4+ T cell, Neutrophil and Dendritic cell.